Oct. 8 (Bloomberg) - Boehringer Ingelheim GmbH abandoned development of its female desire drug flibanserin after U.S. regulators said the pill wasn’t proven to be safe and effective.
Boehringer is still convinced flibanserin would have helped women, Chief Executive Officer Andreas Barner said in an e- mailed statement today. “The decision was not made lightly, considering the advanced stage of development,” he said.
via bloomberg.com
1 comment:
This is indeed a blow to the German drug company that desperately needs new drugs to sell now because it faces the loss of 1 billion euros ($1.5 billion) in annual revenue when its two older medicines, Mirapex for Parkinson’s disease and Flomax for treating prostate enlargement, lose patent protection soon.
UK journalist Ray Moynihan, author of the book 'Sex, Lies, and Pharmaceuticals', wrote in the British Medical Journal this definition of female sexual dysfunction:
“. . . the freshest, clearest example we have of a disease created by pharmaceutical companies to make healthy people think they need medicine”.
This is disease-mongering at its finest! More at 'New Desire Drug Claims That Sex Really IS All In Her Head' at THE ETHICAL NAG: MARKETING ETHICS FOR THE EASILY SWAYED -
http://www.ethicalnag.org/2009/11/15/boehringer-desire-drug/
Post a Comment